Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joanne Chan

Internal Medicine Hanover, PA Medical Doctor

NPI 1467426916 CMS profile 20625

250 Fame Ave, Suite 135, Hanover, PA 17331

Open in the dashboard

General payments

$16,665

1,127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joanne Chan of Hanover, PA is reported in the CMS Open Payments database as having received $16,665 across 1,127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,778 144
2024 General $2,472 142
2023 General $2,516 160
2022 General $2,525 180
2021 General $2,321 178
2020 General $1,879 147
2019 General $2,174 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joanne Chan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joanne Chan were reported at $2,778. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joanne Chan Internal Medicine median Middle half National median
2019 $2,174 $159 $48–$570 $163
2020 $1,879 $119 $33–$402 $114
2021 $2,321 $135 $37–$521 $132
2022 $2,525 $141 $42–$496 $149
2023 $2,516 $149 $45–$519 $160
2024 $2,472 $154 $47–$537 $164
2025 $2,778 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,392 181 payments
  2. AstraZeneca Pharmaceuticals LP $1,728 93 payments
  3. Pfizer Inc. $1,514 122 payments
  4. AbbVie, Inc. $1,352 93 payments
  5. Lilly USA, LLC $1,009 63 payments
  6. GlaxoSmithKline, LLC. $941 74 payments
  7. Astellas Pharma US Inc $693 36 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $601 42 payments
  9. Amarin Pharma Inc. $575 63 payments
  10. Novartis Pharmaceuticals Corporation $479 34 payments
  11. Other $5,381 326 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,443 1,120 payments
  2. Education $222 7 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,560 121 payments
  2. RYBELSUS $1,356 104 payments
  3. FARXIGA $1,115 54 payments
  4. ELIQUIS $606 51 payments
  5. TRELEGY ELLIPTA $548 43 payments
  6. BREZTRI $526 24 payments
  7. QULIPTA $465 37 payments
  8. Vascepa $451 53 payments
  9. MYRBETRIQ $422 28 payments
  10. NURTEC ODT $407 27 payments
  11. Other $15,327 1,012 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 223 drugs

Part D claims

27,858

Median for Internal Medicine: 777

Drug cost

$1,322,562

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 923 $305,368
Nuplazid Pimavanserin Tartrate Brand 30 $144,909
Jardiance Empagliflozin Brand 136 $82,072
Ozempic Semaglutide Brand 59 $75,497
Rybelsus Semaglutide Brand 33 $54,451
Xarelto Rivaroxaban Brand 120 $54,167
Myrbetriq Mirabegron Brand 156 $52,343
Trulicity Dulaglutide Brand 61 $52,298
Farxiga Dapagliflozin Propanediol Brand 24 $27,752
Gemtesa Vibegron Brand 115 $25,733

The 10 drugs with the highest cost, of 223 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$254,446

Of which drugs: $39,120

Medicare patients

589

Average age 81

Services billed

4,020

433 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 50%
Arthritis 43%
Ischemic heart disease 27%
Depression 26%
Alzheimer's or dementia 24%
Atrial fibrillation 22%
Chronic kidney disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 14 1,080 $20,127
Vaccine for influenza for injection into muscle 90653 Office 128 128 $10,112
Pcv20 vaccine im 90677 Office 26 26 $7,493
Influenza vaccine, trivalent derived from cell cultures 90661 Office 28 28 $1,008
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 12 12 $327
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 40 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
$178 33 —
Ozempic
$178 59 —
AIRSUPRA
$158 — —
FARXIGA
$146 24 —
VRAYLAR
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

1,127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record